HRP20100240T1 - Polipeptidi za indukciju zaštitnog imunitetnog odgovora protiv staphylococcus aureus - Google Patents

Polipeptidi za indukciju zaštitnog imunitetnog odgovora protiv staphylococcus aureus Download PDF

Info

Publication number
HRP20100240T1
HRP20100240T1 HR20100240T HRP20100240T HRP20100240T1 HR P20100240 T1 HRP20100240 T1 HR P20100240T1 HR 20100240 T HR20100240 T HR 20100240T HR P20100240 T HRP20100240 T HR P20100240T HR P20100240 T1 HRP20100240 T1 HR P20100240T1
Authority
HR
Croatia
Prior art keywords
seq
polypeptide
sequence
amino acid
immunogen
Prior art date
Application number
HR20100240T
Other languages
English (en)
Croatian (hr)
Inventor
S. Anderson Annaliesa
Ute Jansen Kathrin
Kelly Rosemarie
D. Schultz Loren
L. Montgomery Donna
L. Mcclements William
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34107815&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20100240(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Publication of HRP20100240T1 publication Critical patent/HRP20100240T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HR20100240T 2003-07-24 2004-07-22 Polipeptidi za indukciju zaštitnog imunitetnog odgovora protiv staphylococcus aureus HRP20100240T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48984003P 2003-07-24 2003-07-24
US52011503P 2003-11-14 2003-11-14
PCT/US2004/023523 WO2005009379A2 (en) 2003-07-24 2004-07-22 Polypeptides for inducing a protective immune response against staphylococcus aureus

Publications (1)

Publication Number Publication Date
HRP20100240T1 true HRP20100240T1 (hr) 2010-09-30

Family

ID=34107815

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100240T HRP20100240T1 (hr) 2003-07-24 2004-07-22 Polipeptidi za indukciju zaštitnog imunitetnog odgovora protiv staphylococcus aureus

Country Status (23)

Country Link
US (2) US20060177462A1 (enExample)
EP (1) EP1651166B8 (enExample)
JP (1) JP2007502101A (enExample)
KR (1) KR20060065643A (enExample)
AT (1) ATE457737T1 (enExample)
AU (1) AU2004258979B2 (enExample)
BR (1) BRPI0412799A (enExample)
CA (1) CA2532370A1 (enExample)
CY (1) CY1110028T1 (enExample)
DE (1) DE602004025579D1 (enExample)
DK (1) DK1651166T3 (enExample)
ES (1) ES2342778T3 (enExample)
HR (1) HRP20100240T1 (enExample)
IL (1) IL173253A0 (enExample)
IS (1) IS8213A (enExample)
MX (1) MXPA06000854A (enExample)
NO (1) NO20060898L (enExample)
NZ (2) NZ544542A (enExample)
PL (1) PL1651166T3 (enExample)
PT (1) PT1651166E (enExample)
RU (1) RU2337108C2 (enExample)
SI (1) SI1651166T1 (enExample)
WO (1) WO2005009379A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
WO2005079315A2 (en) * 2004-02-18 2005-09-01 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
KR20070085457A (ko) * 2004-10-25 2007-08-27 더 유니버시티 오브 웨스턴 온타리오 스태필로코쿠스 아우레우스의 철에 의해 조절되는 표면결정인자 ＩｓｄＡ, ＩｓｄＢ, 및 ＩｓｄＣ 기재 백신,조성물 및 방법
GB0526038D0 (en) * 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
AU2007210170A1 (en) * 2006-01-27 2007-08-09 Merck Sharp & Dohme Corp. Antigen-binding proteins targeting S. aureus ORF0657n
JP2010516279A (ja) 2007-01-24 2010-05-20 メルク・シャープ・エンド・ドーム・コーポレイション 表皮ブドウ球菌に対する防御免疫応答を誘導するためのポリペプチド
EP1987836B1 (en) * 2007-05-04 2011-12-21 Martin Krönke Protective staphylococcus aureus vaccine based on cell wall-associated proteins
EP2164869A2 (en) * 2007-05-31 2010-03-24 Merck Sharp & Dohme Corp. Antigen-binding proteins targeting s. aureus orf0657n
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
JP5658564B2 (ja) 2007-08-31 2015-01-28 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
US8758765B2 (en) 2008-07-29 2014-06-24 The University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
EP2376111A4 (en) 2008-11-26 2013-01-09 Merck Sharp & Dohme POLYPEPTIDES FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AGAINST STAPHYLOCOCCUS AUREUS
EP3281947B1 (en) 2009-04-03 2020-02-12 The University of Chicago Compositions and methods related to protein a (spa) variants
NZ612315A (en) 2009-04-14 2014-10-31 Novartis Ag Compositions for immunising against staphylococcus aureus
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
EP2493510B1 (en) 2009-09-30 2020-07-08 GlaxoSmithKline Biologicals SA Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides
PL2493498T3 (pl) 2009-10-30 2017-08-31 Glaxosmithkline Biologicals Sa Oczyszczanie sacharydów otoczkowych staphylococcus aureus typu 5 i typu 8
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
EP2544709A4 (en) * 2010-03-12 2014-01-08 Univ Pennsylvania METHOD FOR PREVENTING AND TREATING THE COLONIZATION OF STAPHYLOCOCCUS AUREUS AND THEIR INFECTIOUS DISEASES AND DISEASES
ES2655701T3 (es) 2010-07-02 2018-02-21 The University Of Chicago Composiciones y métodos relacionados con variantes de la proteína A (SpA)
WO2012021229A1 (en) 2010-07-13 2012-02-16 Merck Sharp & Dohme Corp. Staphylococcus aureus surface protein sa1789 and protective vaccine based thereon
EP2638058B1 (en) 2010-11-12 2017-01-11 Merck Sharp & Dohme Corp. Enolase peptide conjugate vaccines against staphylococcus aureus
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
BR112014004782A2 (pt) 2011-09-01 2017-03-21 Novartis Ag formulações adjuvantes de antígenos de staphylococcus aureus
US9527892B2 (en) 2011-10-31 2016-12-27 Merck Sharp & Dohme Corp. Protective vaccine based on Staphylococcus aureus SA2451 protein
MX2014014804A (es) 2012-06-27 2015-02-12 Hoffmann La Roche Metodo para la elaboracion de conjugados de la region fc de anticuerpos que comprenden por lo menos una entidad de union que se une especificamente a un objetivo y usos del mismo.
EP2867253B1 (en) 2012-06-27 2016-09-14 F. Hoffmann-La Roche AG Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
EP2872173A4 (en) 2012-07-10 2016-03-23 Merck Sharp & Dohme PROTECTIVE VACCINE BASED ON THE STAPHYLOCOCCUS AUREUS PROTEIN SA2493
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
AU2020273471B2 (en) 2019-05-14 2026-05-07 The University Of Chicago Methods and compositions comprising Staphylococcus protein A (SpA) variants
US12528882B2 (en) 2019-09-13 2026-01-20 The University Of Chicago Methods and compositions for treating staphylococcal infections

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
CA2373221A1 (en) * 1999-05-03 2000-11-30 Yashwant M. Deo Human antibodies to staphylococcus aureus
GB0014907D0 (en) * 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
WO2002102829A2 (en) * 2001-06-15 2002-12-27 Inhibitex, Inc. Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
ES2322338T3 (es) * 2001-11-12 2009-06-19 Novo Nordisk A/S Purificacion de peptidos por medio de cromatografia de afinidad con iones metalicos.
JP2005532415A (ja) * 2001-12-11 2005-10-27 メルク　エンド　カムパニー　インコーポレーテッド スタフィロコッカス・アウレウスエキソポリサッカライド及び方法
US20080050361A1 (en) * 2004-10-25 2008-02-28 Heinrichs David E Staphylococcus aureas specific anti-infectives
EP1998800A2 (en) * 2006-01-18 2008-12-10 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins

Also Published As

Publication number Publication date
EP1651166B8 (en) 2010-05-19
DE602004025579D1 (de) 2010-04-01
ATE457737T1 (de) 2010-03-15
JP2007502101A (ja) 2007-02-08
PL1651166T3 (pl) 2010-08-31
US20100247561A1 (en) 2010-09-30
CA2532370A1 (en) 2005-02-03
RU2006105498A (ru) 2006-09-10
WO2005009379A3 (en) 2006-11-30
NZ544542A (en) 2009-01-31
IS8213A (is) 2005-12-30
MXPA06000854A (es) 2006-03-30
DK1651166T3 (da) 2010-05-31
NZ570750A (en) 2009-12-24
IL173253A0 (en) 2006-06-11
NO20060898L (no) 2006-04-24
AU2004258979A1 (en) 2005-02-03
AU2004258979B2 (en) 2007-12-06
KR20060065643A (ko) 2006-06-14
EP1651166B1 (en) 2010-02-17
PT1651166E (pt) 2010-04-23
US20060177462A1 (en) 2006-08-10
EP1651166A4 (en) 2008-03-05
EP1651166A2 (en) 2006-05-03
RU2337108C2 (ru) 2008-10-27
BRPI0412799A (pt) 2006-09-26
WO2005009379A2 (en) 2005-02-03
ES2342778T3 (es) 2010-07-14
CY1110028T1 (el) 2015-01-14
SI1651166T1 (sl) 2010-06-30

Similar Documents

Publication Publication Date Title
RU2006105498A (ru) Полипептиды для индукции защитного иммунного ответа против staphylococcus aureus
CN101516395B (zh) 抗屈曲病毒感染的疫苗
JP2007502101A5 (enExample)
PH12021550030A1 (en) Nucleotide sequences encoding peptide antigens of sars-cov-2 virus and use thereof
JP2009540801A5 (enExample)
EP1578922A2 (en) Replikin peptides in rapid replication of glioma cells and in influenza epidemics
CA3233697A1 (en) Recombinant fusion protein derived from hr region of s2 protein of sars-cov-2 and application of recombinant fusion protein
JP7146926B2 (ja) Ｃｄ４ヘルパーｔ細胞エピトープの融合ペプチドおよびそのワクチン
RU2012147590A (ru) Пептиды cdca5 и содержащие их вакцины
ES2366176T3 (es) Citocinas aviares novedosas y secuencias genéticas que codifican para las mismas.
IE871169L (en) Vaccine against varicella-zoster virus
JP2012517239A5 (enExample)
CN113603754B (zh) 一种水禽h5n8亚型流感病毒ha重组蛋白及其制备方法与应用
JPS59501866A (ja) 腸内ウイルスに対するワクチン接種に有用なポリペプチド
CN107698665B (zh) 一种抗病毒多肽、编码基因、载体、宿主菌及应用
TW200716166A (en) Lawsonia intracellularis immunological proteins
CN115867662A (zh) 形成三聚体的新型冠状病毒肺炎(covid-19)重组刺突蛋白、在植物中大量产生重组刺突蛋白的方法和基于其制备疫苗组合物的方法
HRP20100340T1 (hr) Polipeptidi koji imaju antimikrobno djelovanje i polinukleotidi koji ih kodiraju
CN103352047A (zh) 旋毛虫肌幼虫es抗原基因疫苗及其制备方法
CN102241748A (zh) D29分枝杆菌噬菌体来源的pk34多肽及其应用
Shao et al. DNA fragment encoding human IL-1β 163–171 peptide enhances the immune responses elicited in mice by DNA vaccine against foot-and-mouth disease
KR101127926B1 (ko) 해수어 이리도바이러스 항원성 펩타이드 및 이를 이용한 이리도바이러스 예방용 백신
CN101544693A (zh) 重组胸腺素α1二串体蛋白及其制备方法
CN115850398A (zh) 新型冠状病毒奥密克戎系列变异株的多肽组合物及其应用
KR20210002050A (ko) 구제역 바이러스 백신 조성물